If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
== Political career == He was first elected to the Lok Sabha in the 2009 Indian general election, representing Anandpur Sahib for the Indian National Congress (INC). He would be reelected in the 2014 and 2019 Indian general elections from Ludhiana. In 2021, he served as the INC's leader in the Lok Sabha. He has sought election to the Punjab Legislative Assembly from Jalalabad in 2017, losing to Sukhbir Singh Badal. In January 2021, he was assaulted at the Singhu border during a Jan Sansad program. In 2023, he received a bomb threat via a WhatsApp call. Prior to the 2024 Indian general election, Bittu joined the Bharatiya Janata Party on March 24, 2024. He lost to Amrinder Singh Raja Warring in Ludhiana, but was appointed to the third Modi ministry as Minister of State for Railways and as the Minister of State for Food Processing Industries. He was later elected to the Rajya Sabha from Rajasthan between 2024 to 2026. He is the grandson of former Punjab Chief Minister Beant Singh.
=== Thioredoxin reductase === Thioredoxin reductase uses a cysteine-selenocysteine pair to reduce the disulfide in thioredoxin. The selenocysteine is arranged in an unusual Sec-His-Glu catalytic triad, which tunes its pKa.
Melatonin, the hormone produced in the pineal gland in the brain and secreted in dim light and darkness, among its other functions, promotes sleep in diurnal mammals. It activates the melatonin MT1 and MT2 receptors to produce beneficial effects on sleep, therefore being used exogenously for mild insomnia. A small improvement in sleep onset and total sleep time by using melatonin has been shown in recent systematic reviews. Synthetic analogues of melatonin, or melatonin receptor agonists, have also been made. Among these, ramelteon and tasimelteon are used for sleep disorders. Agomelatine is an antidepressant of this class, with some studies also reporting an effect on sleep.
Sources: en.wikipedia.org
1 November – A pooled analysis indicates that globally over half of all preschool-aged children and over two-thirds of all nonpregnant women of reproductive age are deficient in at least one of three micronutrients each. The study notes required data is scarce and such deficiencies can constrain physical and (neurocognitive) development and compromise health. 2 November – Scientists show that cells move faster in thicker (higher viscosity) fluids. Cancer cells can form memory of extracellular fluid, helping them to form distant cancerous colonies more efficiently when exposed to fluids of higher viscosities. 3 November – Astronomers using the IXPE space observatory report that 4U 0142+61, a magnetar found 13,000 light-years from Earth, likely has a solid surface with no atmosphere. 4 November – The discovery of Gaia BH1, a binary system containing what is likely the closest known black hole to Earth, is reported by astronomers in the U.S. 6–18 November – The 2022 United Nations Climate Change Conference (COP27) on climate change mitigation takes place in Sharm el-Sheikh, Egypt. 7 November The first clinical trial of laboratory-grown red blood cells transfused into people begins. Scientists warn about summarized effects of climate change on insects, among other novel stressors, which may "drastically reduce our ability to build a sustainable future based on healthy, functional ecosystems", providing several recommended mitigation options. The development of organic artificial neurons that function in and with biological systems, partly (see e.g.
In 1910, when Loeb moved to The Rockefeller Institute for Medical Research in New York, Robertson was promoted to Associate Professor of Physiological Chemistry within the School of Medicine; and, in 1916, he was appointed as full Professor of Biochemistry in the new, separate, Department of Biochemistry and Pharmacology that had just been established in the university's School of Medicine. By this time, through his "investigat[ions of the] diverse aspects of mechanisms of growth and longevity in plants, animals and humans", Robertson had already "gained international repute as a leader in the field of biochemistry".
=== Kl--Ku === Martin Heinrich Klaproth (1743–1817), German chemist, who discovered uranium and zirconium, and contributed to the discovery of other elements Trevor Kletz (1922–2013), British promoter of industrial safety Aaron Klug (1926–2018), winner of the 1982 Nobel Prize in Chemistry for developing crystallographic electron microscopy Emil Knoevenagel (1865–1921) German organic chemist, known for the condensation reaction of carbonyl compounds with active methylene compounds Jeremy Randall Knowles (1935–2008), British physical organic chemist known for studies of chemical mechanisms, especially in enzyme catalysis William Standish Knowles (1917–2012), 2001 Nobel Prize in Chemistry for work on asymmetric synthesis, specifically in hydrogenation reactions Walter Kohn (1923–2016), 1998 Nobel Prize in Chemistry for contributions to the understanding of the electronic properties of materials Adolph Wilhelm Hermann Kolbe (1818–1884), German chemist known for Kolbe nitrile synthesis Izaak Kolthoff (1894–1993), Dutch-American chemist with abundant published research in diverse fields of analysis, the "Father of Analytical Chemistry" Arthur Kornberg (1918–2007), American biochemist, Nobel Prize in Chemistry (1959) for discovery of DNA polymerase Hans Kornberg (1928–2019), British biochemist known for research in microbial biochemistry Roger D. Kornberg (born 1947), 2006 Nobel Prize in Chemistry for elucidation of how genetic information from DNA is copied to RNA Teresa Kowalska (1946–2023), Polish chemist, specialized in the theory and application of chromatography Hans A.
Self-assembly is a scalable and parallel process which can involve large numbers of components in a short timeframe. Can result in structural dimensions across orders of magnitude, from nanoscale to macroscale. Is relatively inexpensive compared to the top-down assembly approach, which often consumes large amounts of finite resources. Natural processes that drive self-assembly tend to be highly reproducible. The existence of life is strongly dependent on the reproducibility of self-assembly. Challenges There exist several outstanding challenges in self-assembly, due to a variety of competing factors. Currently self-assembly is difficult to control on large scales, and to be widely applied we will need to ensure high degrees of reproducibility at these scales. The fundamental thermodynamic and kinetic mechanisms of self-assembly are poorly understood - the basic principles of atomistic and macroscale processes can be significantly different than those for nanostructures. Concepts related to thermal motion and capillary action influence equilibrium timescales and kinetic rates that are not well defined in self-assembling systems. Top-down vs bottom-up synthesis
Sources: en.wikipedia.org
Furthermore, the rate of plutonium elimination in the excreta differed between species of animals by as much as a factor of five. Such variation made it extremely difficult to estimate what the rate would be for human beings.
Oswald Avery showed in 1943 that DNA was likely the genetic material of the chromosome, not its protein; the issue was settled decisively with the 1952 Hershey–Chase experiment—one of many contributions from the so-called phage group centered around physicist-turned-biologist Max Delbrück. In 1953 James Watson and Francis Crick, building on the work of Maurice Wilkins and Rosalind Franklin, suggested that the structure of DNA was a double helix. In their famous paper "Molecular structure of Nucleic Acids", Watson and Crick noted coyly, "It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material." After the 1958 Meselson–Stahl experiment confirmed the semiconservative replication of DNA, it was clear to most biologists that nucleic acid sequence must somehow determine amino acid sequence in proteins; physicist George Gamow proposed that a fixed genetic code connected proteins and DNA. Between 1953 and 1961, there were few known biological sequences—either DNA or protein—but an abundance of proposed code systems, a situation made even more complicated by expanding knowledge of the intermediate role of RNA. In 1961, it was demonstrated that when a gene encodes a protein, three sequential bases of a gene's DNA specify each successive amino acid of the protein. Thus the genetic code is a triplet code, where each triplet (called a codon) specifies a particular amino acid.
In December 2018, CIJA chief Stephen Rapp who formerly served as the US Ambassador for Global Criminal Justice, stated that war-crimes committed by the Syrian regime constituted a "solid kind of evidence that we haven't really had since Nuremberg, when the Nazis were prosecuted." The proofs of documented crimes included a vast array of sources, ranging from 2 million video footages to the documents seized from the Baathist regional committees and command crisis centres. Rapp asserted that despite Russian objections in the UN Security Council, the evidences are sufficient for an international arrest warrant.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.